Elmiron Lawsuits Filed for Patients with Vision Loss Due to Elmiron Use
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
We are handling Elmiron lawsuits for patients who have suffered vision loss due to their use of Elmiron. These Elmiron lawsuits are filed against the drug companies responsible for Elmiron. This is because — despite a growing number of Elmiron-related vision loss case reports in the medical literature over the past few years — it was not until June 2020 that any warning about eye problems was included in the Elmiron drug label here in the US.
This Elmiron label change in June 2020 finally added some warnings for serious eye problems such as retinal pigmentary changes and pigmentary maculopathy. From our perspective, these warnings about Elmiron eye side effects were long overdue.
We are currently investigating possible Elmiron lawsuits for patients diagnosed with eye problems such as:
- Vision Loss / Blindness
- Maculopathy (retinal or pigmentation)
- Retinal Pigmentary Endothelium Injury (RPE)
- Pigmentation Maculitis
- Macular Degeneration (pigmentation or dry)
It is important to know that our Elmiron lawsuits for patients who have suffered vision loss are filed only against the pharmaceutical companies responsible for Elmiron — not the doctors who prescribed the Elmiron as a treatment for their bladder diseases.
Significantly, it is not necessary for the patient to have been using Elmiron regularly right up until the time when their Elmiron-related vision loss was diagnosed in order to file an Elmiron lawsuit. That is, unlike most other drug injury cases, the patient could have stopped using Elmiron months before a medical doctor was able to diagnose their eye problem.
Please feel free to contact us if we can be of assistance to you in regards to a possible Elmiron lawsuit.
We encourage you to submit an Elmiron Case Evaluation Form online – it is free, confidential, and there is no obligation. Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about a possible drug injury case. Either way, you will get Mr. Lamb’s impressions – not an intake person, a paralegal, nor some other lawyer – about your case based on his many years of experience.
Most Recent Article About Elmiron
In this post, we look at some relatively recent research regarding the still-emerging drug safety issue of Elmiron and maculopathy, i.e., maculopathy is an Elmiron vision side effect.
According to “Screening needed for pentosan polysulfate sodium-associated maculopathy”, published on September 2, 2021, by Ocular Surgery News:
In most cases, retinal findings do not appear until a patient has been on [Elmiron] for 10 to 15 years, according to Elliott Sohn, MD, of the University of Iowa. Because patients generally start to present with interstitial cystitis in their 40s, once they start to develop maculopathy, it is easily confused with macular degeneration.
“The maculopathy appears to be dose dependent and most often seen when the patient has been on [Elmiron] for a total cumulative dose of 1,500 g,” Sohn said. “A lot more research needs to be done to better understand why and how this is happening, as well as the prevalence of it.”
Two medical journal articles published in 2021 have presented some of this needed research about Elmiron and maculopathy.
To read more of this article, click below:
First, from the Abstract for this study report published in the September 1, 2021 edition of The Journal of Urology, “PD01-09 PATIENT PERCEPTION OF OCULAR RISK IN PENTOSAN POLYSULFATE USE FOR INTERSTITIAL CYSTITIS”:
- CONCLUSIONS: While the mechanism of maculopathy in [Elmiron] use is not fully understood, this risk must be weighed against its potential benefit as a treatment for interstitial cystitis. Physicians should counsel patients on risk of ocular complication in long term and high dose [Elmiron] use, and consider alternative therapies and early ophthalmologic referral in patients with lifetime cumulative doses [of Elmiron] greater than 500 g.
Second, from the Abstract for this study report published in the February 11, 2021 edition of the medical journal Clinical Ophthalmology, “Maculopathy Secondary to Pentosan Polysulfate Use: A Single-Center Experience”:
- Conclusion: A novel drug-induced maculopathy has been associated with [Elmiron] use with a distinct clinical constellation that can be accurately identified with multimodal imaging.
Of course, we will continue to monitor this still-emerging drug safety issue of Elmiron and maculopathy.
Our law firm is investigating possible Elmiron drug injury lawsuits for cases of an Elmiron vision side effect such as retinal pigmentary changes and pigmentary maculopathy resulting in vision loss.[View article in full at original source]
Our earlier articles about Elmiron:
- A 2021 Look at the Increased Risk of Elmiron-associated Pigmentary Maculopathy
- New Elmiron Medication Guide Points Out Retinal Pigmentary Eye Problems
- Elmiron Can Double the Risk of Pigmentary Maculopathy or Macular Degeneration
- Maculopathy Patients Should be Asked About Any Elmiron Use in Past
- Elmiron Legal Cases for Eye Damage and Retinal Injury Are Consolidated in Elmiron MDL
- Elmiron Updates: Legal, Medical, and Regulatory – December 2020
- Are Elmiron Side Effects Risks for Eye and Vision Are Greater Than Its Bladder Treatment Benefits?
- Elmiron Lawsuits Being Filed Against Drug Companies for Elmiron-Related Eye Problems
- FDA Announces Elmiron Drug Safety-Related Labeling Changes
- Elmiron Potentially Linked to Severe Eye Disorders